Patent US4397846A successfully refreshed from Google Patents.
US4397846A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Storage-stable lipid vesicles and method of preparation
Assignee: Individual
•
Filing: 1981-05-15
•
Granted: 1983-08-09
•
Expires: 2001-05-15
Abstract
Abstract Lipid vesicles, such as those containing inositol hexaphosphate useful for improving the oxygen-release of intact erythrocytes, may be rendered stable to long term storage at temperatures below the freezing point of the encapsulated solution, by rapid freezing at a temperature of from about -196° C. to about -30° C.
Inventors
- 👤 Murray Weiner
- 👤 Klaus Gersonde
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 22:24
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K9/1277
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
75 words
The process for preparing an aqueous lipid vesicle suspension, wherein a biologically active agent is encapsulated within a unilamellar phopholipid membrane, stable to long term storage at temperatures of -20° C. and below, which comprises rapidly freezing the lipid vesicle suspension at a temperature of from about -196° C. to about -30° C., wherein the lipid vesicle suspension is frozen in a liquid propane bath at a temperature of from -190° C. to -141° C.
Claim 2
Dependent Claim
75 words
The process for preparing an aqueous lipid vesicle suspension, wherein a biologically active agent is encapsulated within a unilamellar phopholipid membrane, stable to long term storage at temperatures of -20° C. and below, which comprises rapidly freezing the lipid vesicle suspension at a temperature of from about -196° C. to about -30° C., wherein the lipid vesicle suspension is frozen in a liquid propane bath at a temperature of from -190° C. to -141° C.
Claim 3
Dependent Claim
15 words
The process according to claim 1 wherein the encapsulated biologically active agent is inositol hexaphosphate.
Claim 4
Dependent Claim
30 words
The process according to claim 1 wherein the phospholipid membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a molar ratio of from 10 to 5:from 4 to 1:from 10 to 3.
Claim 5
Dependent Claim
18 words
The process of claim 3 wherein the membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a ratio of 8:2:7.
Claim 6
Dependent Claim
25 words
A storage stable lipid vesicle suspension prepared according to claim 1 wherein the encapsulated biologically active agent is inositol hexaphosphate in an aqueous, buffered solution.
Claim 7
Dependent Claim
33 words
The storage stable lipid vesicle suspension of claim 5 wherein the phospholipid membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a molar ratio of from 10 to 5:from 4 to 1:from 10 to 3.
Claim 8
Dependent Claim
23 words
The storage stable lipid vesicle suspension of claim 6 wherein the phospholipid membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a ratio of 8:2:7.
Claim 9
Dependent Claim
110 words
In a process for preparing an aqueous lipid vesicle suspension, a biologically active agent being encapsulated in an aqueous buffered solution within a unilamellar phospholipid membrane in said suspension, and wherein said suspension has a predetermined freezing point, the steps comprising rapidly freezing the lipid vesicle suspension at a temperature of from about -196° C. to about -30° C. following preparation of said lipid vesicle suspension, subsequently storing said lipid vesicle suspension at a temperature below said freezing point so as to be stable for long term storage, and thereafter thawing said lipid vesicle suspension to a temperature suitable for said lipid vesicle suspension to be carried into living cells.
Claim 10
Dependent Claim
110 words
In a process for preparing an aqueous lipid vesicle suspension, a biologically active agent being encapsulated in an aqueous buffered solution within a unilamellar phospholipid membrane in said suspension, and wherein said suspension has a predetermined freezing point, the steps comprising rapidly freezing the lipid vesicle suspension at a temperature of from about -196° C. to about -30° C. following preparation of said lipid vesicle suspension, subsequently storing said lipid vesicle suspension at a temperature below said freezing point so as to be stable for long term storage, and thereafter thawing said lipid vesicle suspension to a temperature suitable for said lipid vesicle suspension to be carried into living cells.
Claim 11
Dependent Claim
27 words
The process as claimed in claim 8 further comprising the step of ensonifying said liquid vesicle suspension at an energy of about 100 watts per square centimeter.
Claim 12
Dependent Claim
26 words
The process as claimed in claim 8, wherein said liquid vesicle suspension is stored at a temperature range from about -20° C. to about -30° C.
Claim 13
Dependent Claim
23 words
A storage stable lipid vesicle suspension prepared according to the process of claim 9, and wherein the biologically active agent includes inositol hexaphosphate.
Claim 14
Dependent Claim
17 words
A storage stable lipid vesicle suspension prepared according to the procedure of claim 1 or claim 9.
References Cited (Backward Citations)
US4311712A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-08 | 1987-02-07 | 1987-08-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-08 | 1991-02-07 | 1991-08-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-08 | 1995-02-07 | 1995-08-09 | $7700.00 | Window Closed / Lapsed |